Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported ...

STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks ...

New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic ...

LEXINGTON, MA, USA I July 16, 2025 I Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New ...

We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, ...

SEONGNAM, South Korea I July 17, 2025 I SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to ...

PITTSBURGH, PA, USA I July 18, 2025 I Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, ...

The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...